1. Home
  2. DERM vs IPHA Comparison

DERM vs IPHA Comparison

Compare DERM & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DERM

Journey Medical Corporation

HOLD

Current Price

$5.07

Market Cap

135.3M

Sector

Health Care

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.46

Market Cap

131.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DERM
IPHA
Founded
2014
1999
Country
United States
France
Employees
N/A
163
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
135.3M
131.4M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
DERM
IPHA
Price
$5.07
$1.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$12.67
$5.75
AVG Volume (30 Days)
154.6K
23.2K
Earning Date
05-13-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
34.72
N/A
EPS
N/A
N/A
Revenue
$61,858,000.00
N/A
Revenue This Year
$39.72
$180.36
Revenue Next Year
$63.24
N/A
P/E Ratio
N/A
N/A
Revenue Growth
10.20
N/A
52 Week Low
$4.31
$1.18
52 Week High
$9.56
$2.63

Technical Indicators

Market Signals
Indicator
DERM
IPHA
Relative Strength Index (RSI) 41.85 50.44
Support Level $4.85 $1.35
Resistance Level $5.50 $1.80
Average True Range (ATR) 0.27 0.08
MACD 0.07 -0.00
Stochastic Oscillator 41.82 50.00

Price Performance

Historical Comparison
DERM
IPHA

About DERM Journey Medical Corporation

Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: